{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:17:07Z","timestamp":1791227827974,"version":"4.1.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1097\/wnf.0000000000000041","type":"journal-article","created":{"date-parts":[[2014,7,3]],"date-time":"2014-07-03T15:44:54Z","timestamp":1404402294000},"page":"116-122","source":"Crossref","is-referenced-by-count":34,"title":["Influence of the Nonergot Dopamine Agonist Piribedil on Vigilance in Patients With Parkinson Disease and Excessive Daytime Sleepiness (PiViCog-PD)"],"prefix":"10.1097","volume":"37","author":[{"given":"Karla","family":"Eggert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"\u00d6hlwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kassubek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kupsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Ceballos-Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Ehret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Polzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Klostermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Haag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Hermsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Lohm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Wangemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang H.","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210203","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1532-5415.2000.tb06891.x","article-title":"Predictors of nursing home placement in Parkinsons disease: a population-based study.","volume":"48","author":"Aarsland","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"R2-6-20210203","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/mds.22643","article-title":"Colosimo, et al. The Priamo study: multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinsons disease.","volume":"24","author":"Barone","year":"2009","journal-title":"Mov Disord"},{"key":"R3-6-20210203","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/mds.10417","article-title":"Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinsons disease.","volume":"18","author":"Paus","year":"2003","journal-title":"Mov Disord"},{"key":"R4-6-20210203","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1017\/S1092852900013560","article-title":"Non-motor aspects of Parkinsons diesease.","volume":"11","author":"Borek","year":"2006","journal-title":"CNS Spectr"},{"key":"R5-6-20210203","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.parkreldis.2008.03.010","article-title":"Impaired attention predicts falling in Parkinsons disease.","volume":"15","author":"Allcoock","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"R6-6-20210203","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/mds.20412","article-title":"Driving in Parkinsons disease: mobility, accidents, and sudden onset of sleep at the wheel.","volume":"20","author":"Meindorfner","year":"2005","journal-title":"Mov Disord"},{"key":"R7-6-20210203","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000276402","article-title":"Excessive daytime sleepiness in Parkinsons disease: characteristics and determinants.","volume":"63","author":"Poryazova","year":"2010","journal-title":"Eur Neurol"},{"key":"R8-6-20210203","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1212\/01.WNL.0000078194.53210.48","article-title":"Low levels of ventricular CSF orexinhypocretin in advanced Parkinsons disease.","volume":"61","author":"Drouot","year":"2003","journal-title":"Neurology"},{"key":"R9-6-20210203","first-page":"593","article-title":"Sleep attacks and dopamine agonists for Parkinsons disease: what is currently known CNS D","volume":"17","author":"Zesiewicz","year":"2003","journal-title":"rugs"},{"key":"R10-6-20210203","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/11539720-000000000-00000","article-title":"Excessive daytime sleepiness in patients with Parkinsons disease.","volume":"25","author":"Knie","year":"2011","journal-title":"CNS Drugs"},{"key":"R11-6-20210203","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/mds.21727","article-title":"Nighttime sleep problems and daytime sleepiness in Parkinsons disease.","volume":"23","author":"Verbaan","year":"2008","journal-title":"Mov Disord"},{"key":"R12-6-20210203","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/11318330-000000000-00000","article-title":"Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinsons disease.","volume":"27","author":"Wood","year":"2010","journal-title":"Drugs Aging"},{"key":"R13-6-20210203","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.sleep.2005.12.002","article-title":"Vigilance troubles in Parkinsons disease: a subjective and objective polysomnographic study.","volume":"7","author":"Monaca","year":"2006","journal-title":"Sleep Med"},{"key":"R14-6-20210203","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/jpet.102.039867","article-title":"Differential actions of antiparkinson agent at multiple classes of monoaminergic receptor. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.","volume":"303","author":"Milan","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"R15-6-20210203","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pharmthera.2010.06.002","article-title":"From the cell to the clinic: a comparative review of the partial D2D3 receptor agonist and alpha2-adrenoreceptor antagonist piribedil, in the treatment of Parkinsons disease.","volume":"128","author":"Milan","year":"2010","journal-title":"Pharmacol Ther"},{"key":"R16-6-20210203","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.neuroscience.2005.09.031","article-title":"Noradrenergic modulation of cognitive function in rat prefrontal cortex as measured by attentional set shifting capability.","volume":"137","author":"Lapiz","year":"2006","journal-title":"Neuroscience"},{"key":"R17-6-20210203","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00213-004-1869-8","article-title":"Cognitive skill learning in healthy older adults after 2 month of double-blind treatment with piribedil.","volume":"176","author":"Peretti","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"R18-6-20210203","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.pnpbp.2006.06.017","article-title":"Effects of the dopamine agonist piribedil on prefrontal temporal cortical network function in normal aging as assessed by verbal fluency.","volume":"31","author":"Gierski","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R19-6-20210203","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1472-8206.2002.00070.x","article-title":"Psychomotor and cognitive effects of piribedil, a dopamine agonist in young healthy volunteers.","volume":"16","author":"Schuck","year":"2002","journal-title":"Fundam Clin Pharmacol"},{"key":"R20-6-20210203","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/mds.20750","article-title":"The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mgday) with bromocriptine (25 mgday) in early combination with levodopa in Parkinsons disease.","volume":"21","author":"Castro-Caldas","year":"2006","journal-title":"Mov Disord"},{"key":"R22-6-20210203","first-page":"222","article-title":"Clinical Global Impressions. In: Guy W ed. ECDEU Assessment for Psychopharmacology . Rev.","volume":"218-","year":"1976","journal-title":"ed"},{"key":"R23-6-20210203","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth sleepiness scale.","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"key":"R25-6-20210203","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Minimental state. A practical method for grading the cognitive state of patients for the clinician.","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"R27-6-20210203","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/ageing\/24.6.505","article-title":"Self-reported functioning and well-being in patients with Parkinsons disease: comparison of the short-form health survey (SF-36) and the Parkinsons Disease Questionnaire (PDQ-39).","volume":"24","author":"Jenkinson","year":"1995","journal-title":"Age Ageing"},{"key":"R28-6-20210203","first-page":"222","article-title":"ECDEU Assessment for Psychopharmacology . Rev.","volume":"218-","year":"1976","journal-title":"ed"},{"key":"R32-6-20210203","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/jnnp.73.6.629","article-title":"The Parkinsons disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinsons disease.","volume":"73","author":"Chaudhuri","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R33-6-20210203","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1055\/s-0038-1628814","article-title":"Piribedil-ein non-ergot dopaminagonist mit besonderem rezeptorprofil.","volume":"29","author":"Jost","year":"2010","journal-title":"Nervenheilkunde"},{"key":"R34-6-20210203","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/brain\/awt067","article-title":"Parkinsonian apathy responds to dopaminergic stimulation of D2D3 receptors with piribedil.","volume":"136","author":"Thobois","year":"2013","journal-title":"Brain"},{"key":"R35-6-20210203","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1046\/j.1460-9568.1998.00145.x","article-title":"Reduction of noradrenaline impairs attention and dopamine depletion slows responses in Parkinsons disease.","volume":"10","author":"Riekkinen","year":"1998","journal-title":"Eur J Neurosci"},{"key":"R36-6-20210203","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1002\/mds.23190","article-title":"Scales to assess sleep impairment in Parkinsons disease: critique and recommendations.","volume":"16","author":"Hogl","year":"2010","journal-title":"Mov Disord"},{"key":"R37-6-20210203","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00702-003-0027-5","article-title":"Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum.","volume":"110","author":"Gerlach","year":"2003","journal-title":"J Neural Transm"},{"key":"R38-6-20210203","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/jpet.102.039883","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor: III. Agonist and antagonist properties at serotonin, 5-HT (1) and 5-HT (2), receptor subtypes.","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"R39-6-20210203","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/ageing\/30.4.299","article-title":"Determining minimally important differences for the PDQ-39 Parkinsons disease questionnaire.","volume":"30","author":"Peto","year":"2001","journal-title":"Age Ageing"},{"key":"R40-6-20210203","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1600-0404.2003.00231.x","article-title":"Differential response in choice reaction time following apomorphine based on prior dopaminergic treatment.","volume":"109","author":"Muller","year":"2004","journal-title":"Acta Neurol Scand"},{"key":"R41-6-20210203","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0022-510X(00)00436-6","article-title":"Choice reaction time after levodopa challenge in parkinsonian patients.","volume":"181","author":"Muller","year":"2000","journal-title":"J Neurol Sci"},{"key":"R42-6-20210203","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S1388-2457(01)00653-8","article-title":"Delay of simple reaction time after levodopa intake.","volume":"112","author":"Muller","year":"2001","journal-title":"Clin Neurophysiol"},{"key":"R43-6-20210203","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1212\/WNL.38.2.249","article-title":"Dopaminergic effects on simple and choice reaction time performance in Parkinsons disease.","volume":"38","author":"Pullman","year":"1988","journal-title":"Neurology"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0000000000000041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:09:47Z","timestamp":1620976187000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-201407000-00006"}},"subtitle":["An 11-Week Randomized Comparison Trial Against Pramipexole and Ropinirole"],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0000000000000041","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}